Last reviewed · How we verify
NCT03680183
Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)
trial testing Entecavir 1Mg Oral Tablet in Non Small Cell Lung Cancer in 300 participants. Status unknown.
1 March 2019
Quick facts
| Lead sponsor | Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 22 May 2018 |
| Primary completion | 1 March 2019 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Entecavir 1Mg Oral Tablet — full drug profile →
Conditions studied
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
- Hepatitis B — all drugs for Hepatitis B →
Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Who can join
Adults 18 to 70, any sex, with Non Small Cell Lung Cancer or Hepatitis B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will explore the characteristics in clinical pharmacokinetics of gefitinib, erlotinib,afatinib,osimertinib, crizotinib, apatinib, icotinib in Chinese patients of Non-small-cell lung cancer and hepatitis B. The study is self-controlled. The plasma concentration of tyrosine kinase inhibitors will be analyzed before and after system treatment of HBV.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03680183
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
- NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
Other Affiliated Cancer Hospital & Institute of Guangzhou Medical University trials
Trials by the same sponsor.
- NCT07286240 — QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer · Phase 2 · recruiting
- NCT07286253 — QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial · Phase 2 · recruiting
- NCT06594172 — Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy · Phase 2 · not yet recruiting
- NCT06570538 — Analgesic Efficacy of an Opioid-free Postoperative Pain Management Strategy Versus a Conventional Opioid-based Strategy · EARLY_PHASE1 · not yet recruiting
- NCT06327932 — HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03680183 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- Last refreshed: 28 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03680183.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing